Modality
Gene Editing
MOA
RAS(ON)i
Target
PCSK9
Pathway
Proteasome
Alzheimer'sCRCALS
Development Pipeline
Preclinical
~Apr 2023
→ ~Jul 2024
Phase 1
Oct 2024
→ Jun 2025
Phase 1Current
NCT07597196
1,316 pts·CRC
2024-10→2025-06·Recruiting
1,316 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0410mo agoPh2 Data· CRC
Trial Timeline
Q42025Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2025-06-04 · 10mo ago
CRC
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07597196 | Phase 1/2 | CRC | Recruiting | 1316 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |